G Freyer

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. pmc Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
    Salima Hamizi
    Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, France
    Onco Targets Ther 6:89-94. 2013
  2. ncbi request reprint Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study
    Gilles Freyer
    Department of Medical Oncology, Lyon Sud Hospital, 69495 Pierre Benite Cedex, France
    Anticancer Res 33:301-7. 2013
  3. pmc Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    Universite de Lyon, Service d Oncologie Medicale, Centre d Investigation des Thérapeutiques en Oncologie et Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite 69495, France
    Br J Cancer 107:598-603. 2012
  4. doi request reprint Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study
    Gilles Freyer
    Department of Medical Oncology, Centre Hospitalier Lyon Sud and Université de Lyon, France
    Crit Rev Oncol Hematol 80:466-73. 2011
  5. pmc Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite Université Lyon 1, EMR UCBL HCL 3738, Lyon, France
    BMC Cancer 11:478. 2011
  6. ncbi request reprint Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study
    Gilles Freyer
    Université de Lyon and Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Anticancer Res 31:359-66. 2011
  7. ncbi request reprint Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study
    G Freyer
    Service d Oncologie Medicale, Centre Hospitalier Lyon Sud, Pierre Benite
    Ann Oncol 16:1795-800. 2005
  8. ncbi request reprint Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience
    Gilles Freyer
    Medical Oncology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, France
    Clin Oncol (R Coll Radiol) 16:17-23. 2004
  9. ncbi request reprint Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'
    G Freyer
    Centre Hospitalier Lyon Sud, Service d Oncologie, Pierre Benite, France
    Ann Oncol 17:211-6. 2006
  10. ncbi request reprint The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT)
    G Freyer
    Medical Oncology Unit and EA 643, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, Cedex, France
    Lung Cancer 31:247-56. 2001

Detail Information

Publications45

  1. pmc Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
    Salima Hamizi
    Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, France
    Onco Targets Ther 6:89-94. 2013
    ..This review focuses on the development of the subcutaneous trastuzumab formulation and analyzes clinical trials assessing the pharmacokinetics, efficacy, and safety of this new formulation...
  2. ncbi request reprint Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study
    Gilles Freyer
    Department of Medical Oncology, Lyon Sud Hospital, 69495 Pierre Benite Cedex, France
    Anticancer Res 33:301-7. 2013
    ....
  3. pmc Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    Universite de Lyon, Service d Oncologie Medicale, Centre d Investigation des Thérapeutiques en Oncologie et Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite 69495, France
    Br J Cancer 107:598-603. 2012
    ..This phase I cohort study investigated aflibercept (vascular endothelial growth factor (VEGF) trap) plus docetaxel and cisplatin in patients with advanced solid tumours...
  4. doi request reprint Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study
    Gilles Freyer
    Department of Medical Oncology, Centre Hospitalier Lyon Sud and Université de Lyon, France
    Crit Rev Oncol Hematol 80:466-73. 2011
    ..Primary prophylactic G-CSF was given to 49% of patients. In a selected population of elderly patients, 4 cycles of adjuvant TC is feasible without major toxicity, confirming the US Oncology trial data...
  5. pmc Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite Université Lyon 1, EMR UCBL HCL 3738, Lyon, France
    BMC Cancer 11:478. 2011
    ..This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs...
  6. ncbi request reprint Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study
    Gilles Freyer
    Université de Lyon and Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Anticancer Res 31:359-66. 2011
    ....
  7. ncbi request reprint Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study
    G Freyer
    Service d Oncologie Medicale, Centre Hospitalier Lyon Sud, Pierre Benite
    Ann Oncol 16:1795-800. 2005
    ....
  8. ncbi request reprint Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience
    Gilles Freyer
    Medical Oncology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, France
    Clin Oncol (R Coll Radiol) 16:17-23. 2004
    ..Idarubicin, the only orally administrated cytotoxic agent belonging to the anthracycline family, may be a potential alternative to intravenous chemotherapy for this population for quality-of-life reasons...
  9. ncbi request reprint Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'
    G Freyer
    Centre Hospitalier Lyon Sud, Service d Oncologie, Pierre Benite, France
    Ann Oncol 17:211-6. 2006
    ..Treatment of elderly patients with metastatic breast cancer (MBC) is not clearly defined and seems to vary according to the subjective appreciation of the physician...
  10. ncbi request reprint The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT)
    G Freyer
    Medical Oncology Unit and EA 643, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, Cedex, France
    Lung Cancer 31:247-56. 2001
    ..To assess the potential relationships between systemic exposure to doxorubicin, etoposide and ifosfamide at first chemotherapy cycle and therapeutic effect, tumor response, toxicity, and survival, in small cell lung cancer (SCLC) patients...
  11. pmc Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
    G Freyer
    Medical Oncology Unit and EA 643, Centre Hospitalier Lyon Sud, Pierre Benite, Pharmacology Unit, Centre Leon Berard, Lyon, France
    Br J Clin Pharmacol 50:315-24. 2000
    ....
  12. ncbi request reprint Therapeutic advances in the management of metastatic colorectal cancer
    G Freyer
    Medical Oncology Unit, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France
    Expert Rev Anticancer Ther 1:236-46. 2001
    ..In this paper we will review and comment on the results of the major clinical trials published in the past 5 years and propose some decision strategies regarding the main clinical situations met in daily practice...
  13. ncbi request reprint Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations
    G Freyer
    Medical Oncology Unit, Centre Hospitalier Lyon Sud, and EA 643, Université Lyon I, France
    Ann Oncol 12:1461-5. 2001
    ..As shown in a previous study, the knowledge of the genetic risk in individuals belonging to families at risk of medullary-thyroid carcinoma (MTC) could be associated with impaired quality of life (QoL)...
  14. ncbi request reprint Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer
    O Glehen
    Department of Surgery, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Arch Surg 139:20-6. 2004
    ..This study evaluates the efficacy of intraperitoneal chemohyperthermia after cytoreductive surgery in patients with peritoneal carcinomatosis arising from gastric cancer...
  15. ncbi request reprint Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
    O Tredan
    Medical Oncology Department, Hospices Civils de Lyon et Université de Lyon, France
    Ann Oncol 18:256-62. 2007
    ..To determine the feasibility of two chemotherapy regimens in elderly patients with advanced ovarian carcinoma (AOC)...
  16. doi request reprint Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study
    C Falandry
    Universite de Lyon, 69003 Lyon, France
    Breast Cancer Res Treat 116:501-8. 2009
    ..No severe adverse events were reported. Cyclooxygenase-2 inhibitors seemingly contribute to reverse endocrine resistance in breast cancer patients, although further study is necessary to allow development of a new therapeutic strategy...
  17. ncbi request reprint Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
    V Trillet-Lenoir
    Medical Oncology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
    Clin Oncol (R Coll Radiol) 16:196-203. 2004
    ..Computed tomography (CT) is the reference technique for evaluating response to chemotherapy. The potential helpfulness of tumour markers is debated...
  18. ncbi request reprint Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures
    O Glehen
    Department of Surgery, Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
    Ann Surg Oncol 10:863-9. 2003
    ..The aim of this trial was to analyze the mortality and morbidity of 216 consecutive treatments of peritoneal carcinomatosis by IPCH by using a closed abdominal procedure combined with cytoreductive surgery...
  19. ncbi request reprint Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation
    G Freyer
    Unité d Oncologie Médicale, Centre Hospitalier Lyon Sud, France
    Ann Oncol 10:87-95. 1999
    ..Little data are available in the literature, mainly from studies including small numbers of selected and motivated patients...
  20. pmc Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups
    G Freyer
    Medical Oncology Unit and EA 643, Centre Hospitalier Lyon Sud, , Lyon, France
    Br J Cancer 83:431-7. 2000
    ..These results should also be prospectively confirmed in ongoing or future trials using irinotecan, both as a single agent and in combination with other drugs...
  21. doi request reprint Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial
    P Heudel
    Centre Hospitalier Lyon Sud, France
    Clin Oncol (R Coll Radiol) 20:369-74. 2008
    ..To determine the feasibility of radiotherapy-associated capecitabine, irinotecan and oxaliplatin administration at five dose levels for the treatment of locally advanced rectal cancer, with or without metastasis...
  22. pmc Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 100:601-7. 2009
    ..6 and 11.4 months, respectively. The OXA-GE combination has high activity and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA-GE with single-agent treatment is warranted...
  23. ncbi request reprint Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
    C Falandry
    Geriatrics and Oncology Unit, Centre Hospitalier Lyon Sud, Universite Lyon 1, Pierre Benite
    Ann Oncol 24:2808-13. 2013
    ..Two previous GINECO elderly specific studies in advanced ovarian cancer (AOC) patients highlighted the prognostic value of geriatric covariates for overall survival (OS)...
  24. doi request reprint Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial
    C Falandry
    Department of Geriatric Medicine, Centre Hospitalier Lyon Sud, Pierre Benite, Universite Lyon 1, Lyon, France
    Eur J Cancer 49:2806-14. 2013
    ..Metastatic breast cancer chemotherapy in the elderly is considered effective in carefully selected patients, but there is little data regarding its effect in vulnerable patients...
  25. pmc Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements
    B You
    EMR UBCL HCL 3738, Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Lyon, France
    Br J Cancer 108:1810-6. 2013
    ..We previously demonstrated that kinetic modelling of human chorionic gonadotrophin (hCG) measurements could provide such a marker. Here we validate this approach in a large independent patient cohort...
  26. doi request reprint Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients
    N Bakrin
    Department of Oncologic Surgery, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Ann Surg Oncol 19:4052-8. 2012
    ..During the two past decades, a new therapeutic approach to peritoneal carcinomatosis has been developed, combining maximal cytoreductive effort with hyperthermic intraperitoneal chemotherapy (HIPEC)...
  27. ncbi request reprint Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
    B You
    EA 3738, Universite de Lyon, Lyon, France
    Ann Oncol 21:1643-50. 2010
    ..We modeled human chorionic gonadotropin (hCG) decline during MTX therapy using a kinetic population approach to calculate individual hCG clearance (CL(hCG)) and assessed the predictive value of CL(hCG) for MTX resistance...
  28. ncbi request reprint Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial
    G Freyer
    Department of Radiation Oncology, Medical Oncology Unit, Centre Hospitalier Lyon-Sud, , France
    J Clin Oncol 19:2433-8. 2001
    ..Although the MTD was not reached in this study, we recommend oxaliplatin 130 mg/m2 for phase II studies because it is the dose determined from studies in metastatic patients with no toxicity when given concurrently with radiation...
  29. ncbi request reprint Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study
    O Glehen
    Surgical Department, Anesthesiology and Intensive Care Unit, Medical Oncology Department, Centre Hospitalo Universitaire Lyon Sud, Pierre Benite, France
    J Clin Oncol 21:799-806. 2003
    ..To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001...
  30. ncbi request reprint Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
    G Freyer
    Hospices Civils de Lyon, Department of Medical Oncology and EA 643, Universite Claude Bernard Lyon I, France
    J Clin Oncol 21:35-40. 2003
    ..Oral Navelbine (NVB; Pierre Fabre Médicament, Boulogne, France) was given as first-line chemotherapy for locally advanced or metastatic breast carcinoma (ABC)...
  31. ncbi request reprint Quantitative prognostic indices in peritoneal carcinomatosis
    F N Gilly
    Surgical Department, Centre Hospitalo Universitaire Lyon Sud, 69495 Pierre Benite Cedex, France
    Eur J Surg Oncol 32:597-601. 2006
    ..Combinations of these to achieve a complete description of peritoneal lesions prior to and following treatment assist in a correct prognostic assessment for these patients and in a selection of treatment options...
  32. ncbi request reprint A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients
    B Tranchand
    Laboratoire de Pharmacocinetique, Centre Leon Berard, Lyon, France
    Cancer Chemother Pharmacol 43:316-22. 1999
    ..Statistical comparison showed a good concordance between ML and BE estimates (the bias for clearance was -1.72%). The limited-sampling strategy presented herein can thus be used for accurate estimation of VP16 pharmacokinetic parameters...
  33. doi request reprint Chemotherapy may be delivered based on an integrated view of tumour dynamics
    B Ribba
    Universite de Lyon, Lyon, France
    IET Syst Biol 3:180-90. 2009
    ..Physiopathological parameters, in particular those related to cell cycle regulation, may be integrated in PK/PD models aimed at optimising the delivery of phase-specific cytotoxic treatments...
  34. doi request reprint Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer
    C Falandry
    Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Ann Oncol 20:615-20. 2009
    ..Careful monitoring during future trials will be necessary to accurately assess the risk-benefit ratio of combination therapy...
  35. doi request reprint A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment
    R Almufti
    Service d Oncologie Medicale, Investigational Center for Treatments in Oncology and Hematology of Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
    Ann Oncol 25:41-56. 2014
    ..Validation studies are required. Efforts should be made to standardize biomarker kinetic analysis methodologies to ensure the optimized development of novel serum biomarkers and avoid the pitfalls of traditional markers. ..
  36. doi request reprint [Is geriatric assessment adapted to radiotherapy?]
    C Falandry
    Universite de Lyon, 69003 Lyon, France
    Cancer Radiother 12:541-7. 2008
    ....
  37. doi request reprint Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines
    C Falandry
    Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Benite, Universite Lyon 1, Lyon, France
    Eur J Cancer 46:2389-98. 2010
    ..Although international guidelines have standardised conditions for G-CSF administration, real practice seems to vary...
  38. ncbi request reprint Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature
    J Dumortier
    Department of Radiotherapy and Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, France
    Ann Oncol 11:355-8. 2000
    ..When indicated, chemotherapy might require the use of platinum derivatives in this particular type of secondary tumor...
  39. doi request reprint A dynamic model of hand-and-foot syndrome in patients receiving capecitabine
    E Henin
    Universite de Lyon, Lyon, France
    Clin Pharmacol Ther 85:418-25. 2009
    ..This dose-toxicity model will be useful in developing Bayesian individual treatment adaptations and may be of use in the clinic...
  40. ncbi request reprint Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria
    V Trillet-Lenoir
    Department of Medical Oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France
    Br J Radiol 75:903-8. 2002
    ..Since it provides concordant results with a simplified method, the use of RECIST criteria is recommended for evaluation of treatment efficacy in clinical trials and routine practice...
  41. ncbi request reprint [Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature]
    B Ligneau
    Service de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Pierre Benite
    Presse Med 26:458-63. 1997
    ..Type 1 neurofibromatosis considerably increases the risk of cancer development, particularly neurosarcoma. We report a case in a patient with chemosensitive metastatic neurosarcoma...
  42. ncbi request reprint Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry
    J Guitton
    Laboratoire de ciblage thérapeutique en cancérologie, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    Rapid Commun Mass Spectrom 19:2419-26. 2005
    ..This method was sufficiently selective and sensitive for quantification of metabolites in plasma from cancer patients receiving docetaxel chemotherapy, and is suitable for routine analyses during pharmacokinetic studies...
  43. ncbi request reprint Oral vinorelbine: feasibility and safety profile
    A Depierre
    Department of Pneumology, Centre Hospitalier Universitaire Minjoz, , France
    Ann Oncol 12:1677-81. 2001
    ..v. vinorelbine at standard doses. Similarly to i.v. chemotherapy, close haematological monitoring is necessary...
  44. ncbi request reprint Trends in tobacco smoking among adolescents in Lyon, France
    A J Sasco
    Unit of Epidemiology for Cancer Prevention, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    Eur J Cancer 39:496-504. 2003
    ..Not playing sports and not playing with computers were initially associated with an increased risk of regular smoking in grade 3ème...
  45. ncbi request reprint Lethal toxicity of capecitabine due to abusive folic acid prescription?
    C Clippe
    Clin Oncol (R Coll Radiol) 15:299-300. 2003